Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex

a technology of cdca1 and kntc2, which is applied in the field of biochemical science, can solve the problems of poor prognosis of co-activation of cdca1 and kntc2 in lung-cancer patients, and achieve the effects of suppressing expression, effectively suppressing nsclc cell growth, and poor prognosis

Inactive Publication Date: 2011-10-27
ONCOTHERAPY SCI INC
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Inhibiting the CDCA1-KNTC2 complex effectively suppresses the growth of NSCLC cells, providing a potential therapeutic strategy for treating lung cancer by targeting these proteins, which are specifically over-expressed in lung cancer and associated with poor prognosis.

Problems solved by technology

Immunohistochemical analysis of lung-cancer tissue microarrays demonstrated that co-activation of CDCA1 and KNTC2 in lung-cancer patients was associated with poor prognosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
  • Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
  • Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex

Examples

Experimental program
Comparison scheme
Effect test

examples

[0190]The following examples are offered to illustrate, but not to limit the claimed invention.

Materials and Methods

[0191](a) Lung-Cancer Cell Lines and Tissue Samples: The human lung-cancer cell lines used in the following protocols were as follows: lung adenocarcinomas (ADC) A427, A549, LC319, PC3, PC9, PC14, NCI-H23, NCI-H522, and NCI-H1373; bronchioloalveolar cell carcinomas (BAC) NCI-H1666 and NCI-H1781; lung adenosquamous carcinomas (ASC)NCI-H226 and NCI-H647; lung squamous-cell carcinomas (SCC) RERF-LC-AI, SK-MES-1, EBC-1, LC176, LU61, NCI-H520, NCI-H1703, and NCI-H2170; a lung large-cell carcinoma (LCC) LX1; and small cell lung cancers (SCLC) DMS114, DMS273, SBC-3, and SBC-5. All cells were grown in monolayers in appropriate medium supplemented with 10% fetal calf serum (FCS) and were maintained at 37° C. in atmospheres of humidified air with 5% CO2. Human small airway epithelial cells (SAEC) were grown in optimized medium (SAGM) purchased from Cambrex Bio Science Inc. (Walk...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.

Description

[0001]This application is a divisional of U.S. application Ser. No. 11 / 913,142, filed Jan. 28, 2009, which is a U.S. National Stage Application of PCT / JP2006 / 314715, filed Jul. 19, 2006, which claims the benefit of U.S. Provisional Application Ser. No. 60 / 703,704 filed on Jul. 29, 2005, all of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]This invention relates to the field of biological science, more specifically to the field of cancer therapy. In particular, the invention relates to the treatment of cancer based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.BACKGROUND OF THE INVENTION[0003]Lung cancer is one of the most common cancers in the world, and non-small-cell lung cancer (NSCLC) is by far the most common form, accounting for nearly 80% of those ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C12N15/63C07H21/02
CPCG01N2500/02G01N33/57423A61P35/00
InventorNAKAMURA, YUSUKEDAIGO, YATARONAKATSURU, SHUICHI
OwnerONCOTHERAPY SCI INC